Raffi Afeyan joined Flagship as a Principal in 2021. He works as part of a team of entrepreneurial scientists exploring innovative ideas, developing the science, intellectual property, and business strategy that form the foundation of breakthrough startups and operationalizing them through their early stages.
Before joining Flagship, Raffi held a variety of roles within Flagship ecosystem companies. Most recently, he was the VP of Product Strategy and Innovation at Cellarity and at Generate Biomedicines where he focused on exploring how their platforms could be applied to create value across potential program areas.
Prior to that, he was the Senior Director of Strategic Innovation at Axcella Health. There, he led an internal exploration that motivated the company’s development of their current therapeutic modality of endogenous metabolic modulators (EMMs), ultimately leading to their IPO in 2019. He is an author on several published scientific articles, patents and notably is an inventor of Axcella’s two declared candidate drugs currently in clinical development for liver diseases. He previously completed the Flagship Fellowship Program in 2014.
Raffi earned his Ph.D. and M.S. in Biomedical Engineering from Boston University, specializing in synthetic biology under Jim Collins. He earned a B.Eng in Chemical Engineering from McGill University.